Remdesivir, which became the first drug to receive full FDA approval to treat COVID-19 Oct. 22, drove Gilead’s revenue up by 17 percent from last year. The drugmaker has been selling remdesivir under the brand name Veklury.
Remdesivir generated $873 million in sales during the third quarter, mostly in the U.S., CNBC reported. Gilead’s total sales were $6.5 billion in the third quarter, up $5.5 billion from last year and higher than the $6.3 billion analysts predicted.
Excluding remdesivir, the company’s total sales increased 2 percent, to $5.6 billion, compared to last year’s, according to CNBC.
Read the full article here.
More articles on pharmacy:
Kroger-owned pharmacies offering in-store rapid COVID-19 antibody tests
Eli Lilly inks $375M deal with US to supply COVID-19 antibody drug
Sunstar recalls gingivitis drug due to potential bacterial contamination
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.